中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2010年
14期
1901-1902
,共2页
高血压肾损害%尿蛋白%贝那普利%金水宝胶囊
高血壓腎損害%尿蛋白%貝那普利%金水寶膠囊
고혈압신손해%뇨단백%패나보리%금수보효낭
Hypertensive disease%Kidney damage%Urine protein%Ccr%Benazepril%Jinshuibao capsules
目的 观察贝那普利联合金水宝胶囊对高血压肾损害患者尿蛋白、肾功能的影响.方法 选择高血压肾损害患者47例,随机分为联合组和对照组.对照组给予含贝那普利的常规治疗,联合组在此基础上加用金水宝胶囊.观察治疗后9周后的相关临床指标变化,并计算内生肌酐清除率(Ccr).结果 两组患者治疗9周后,24 h尿蛋白均降低(t1=1.9997,t2=3.3088,P<0.05或P<0.01),内生肌酐清除率均升高(t1=1.3990,t2=1.4442,P>0.05),血压均有所改善(t1=2.0047,t2=2.4557,t3=2.0426,t4=2.4026,均P<0.05);与对照组相比,联合组24 h尿蛋白降低更明显(t=2.0015,P<0.05).结论 贝那普利联合金水宝胶囊治疗高血压肾损害有明显减少患者蛋白尿作用.
目的 觀察貝那普利聯閤金水寶膠囊對高血壓腎損害患者尿蛋白、腎功能的影響.方法 選擇高血壓腎損害患者47例,隨機分為聯閤組和對照組.對照組給予含貝那普利的常規治療,聯閤組在此基礎上加用金水寶膠囊.觀察治療後9週後的相關臨床指標變化,併計算內生肌酐清除率(Ccr).結果 兩組患者治療9週後,24 h尿蛋白均降低(t1=1.9997,t2=3.3088,P<0.05或P<0.01),內生肌酐清除率均升高(t1=1.3990,t2=1.4442,P>0.05),血壓均有所改善(t1=2.0047,t2=2.4557,t3=2.0426,t4=2.4026,均P<0.05);與對照組相比,聯閤組24 h尿蛋白降低更明顯(t=2.0015,P<0.05).結論 貝那普利聯閤金水寶膠囊治療高血壓腎損害有明顯減少患者蛋白尿作用.
목적 관찰패나보리연합금수보효낭대고혈압신손해환자뇨단백、신공능적영향.방법 선택고혈압신손해환자47례,수궤분위연합조화대조조.대조조급여함패나보리적상규치료,연합조재차기출상가용금수보효낭.관찰치료후9주후적상관림상지표변화,병계산내생기항청제솔(Ccr).결과 량조환자치료9주후,24 h뇨단백균강저(t1=1.9997,t2=3.3088,P<0.05혹P<0.01),내생기항청제솔균승고(t1=1.3990,t2=1.4442,P>0.05),혈압균유소개선(t1=2.0047,t2=2.4557,t3=2.0426,t4=2.4026,균P<0.05);여대조조상비,연합조24 h뇨단백강저경명현(t=2.0015,P<0.05).결론 패나보리연합금수보효낭치료고혈압신손해유명현감소환자단백뇨작용.
Objective To observe influence of Benazepril combined with Jinshuibao capsules on urine protein and Ccr in patients hypertensive renal disease. Methods 47 hypertensive renal disease patients were randomly divided into control group and combine group. Patients in control group were treated with Benazepril, while patients in combined group were treated Jinshuibao plus Benazepril. Clinic index change after treatment for 9 weeks was observed, and calculation endogenous creatinine clearance rate was calculated. Results After treatment for 9 weeks urine protein in 24 hours of two groups were both lower than before( t1 = 1. 9997 ,t2 = 3.3088 ,P < 0. 05 or P < 0. 01 ),while the endogenous creatinine clearance rate were both higher than before ( t1 = 1. 3990, t2 = 1. 4442, P > 0. 05 ), and the press were all in improvment ( t1 = 2.0047, t2 = 2.4557, t3 = 2.0426, t4 = 2.4026, P < 0. 05 ); urine protein in 24 hours of combine group was lower than control group( t = 2.0015,P < 0. 05) Conclusion Benazepril plus Jinshuibao capsules could obviously abate urine protein on patients with hypertensive disease and hypertensive renal disease